PharmaCyte Biotech
PMCB
21 hedge funds and large institutions have $934K invested in PharmaCyte Biotech in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 5 closing their positions.
100% more call options, than puts
Call options by funds: $14K | Put options by funds: $7K
2.14% less ownership
Funds ownership: 10.76% → 8.62% (-2.1%)
19% less funds holding
Funds holding: 26 → 21 (-5)
41% less capital invested
Capital invested by funds: $1.58M → $934K (-$643K)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C
Covestor
London,
United Kingdom
|
+$85 |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$50 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$400K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$5.98K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5K |
| 5 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
-$1.53K |
PMCB Hedge Fund Activity: Q4 2024 in Review
21 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q4 2024, worth a combined $934K — down 41% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PMCB and 1 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was Covestor, adding an estimated $85. The largest seller was K2 Principal Fund, exiting entirely with an estimated $400K sold.
- 21 institutional investors held PharmaCyte Biotech (PMCB) as of Q4 2024, down from 26 in Q3 2024.
- Funds reported $934K of PharmaCyte Biotech stock for Q4 2024, down 41% quarter-over-quarter.
- 1 fund opened new PharmaCyte Biotech positions in Q4 2024 and 5 closed out, a net change of -4 holders.
- The largest PharmaCyte Biotech buyer in Q4 2024 was Covestor, an estimated $85 added.
- The largest PharmaCyte Biotech seller in Q4 2024 was K2 Principal Fund, an estimated $400K sold.
Based on aggregated 13F filings for Q4 2024.